Vyripharm Enterprises, Inc.

Vyripharm LLC

The University of Texas System

Jerry L Bryant, Jr

Tori M Strong

Elias Bernard Jackson, Jr

David J Yang

Dong-Fang Yu

Chang-Sok Oh

Embodiments of the disclosure provide a method of man-aging information related to aproduct across a distributed validated system. The method includes enabling an authorized user to create a plurality of data containing genetic profile of a seed, plant growth conditions of a crop, and manufacturing information used for production of theproduct, and measurements of quality and quantity of desired components and undesired components in theproduct. The method includes associating the plurality of data to a record which is identified by a unique identifier. The method includes storing the record into a memory for access by one or more of a plurality of authorized users using the unique identifier. The method includes analyzing theproduct to determine the quality and quantity of desired components and undesired components in theproduct. The method includes determining concentration of cannabinoids in theproduct.

Compositions containing cannabinoid analog conjugates and methods of use

Compositions and methods for the personalized and targeted therapeutic treatment of diseases and disorders, including the treatment of pain, inflammation, and infectious diseases in a subject. In particular, labeled synthetic cannabinoid therapeutic compositions are provided that include a conjugate of a synthetic cannabinoid compound, a chelator, and a label, that when coupled with imaging may be used to determine in real time optimal dosing and targeting of particular pathways and tissues to provide personalized therapies. Combination therapies are also provided that include one or more synthetic cannabinoid compound and at least one active pharmaceutical ingredient.

Synthetic cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases

Embodiments of the disclosure provide a method of managing information related to aproduct across a distributed validated system. The method includes enabling an authorized user to create a plurality of data containing genetic profile of a seed, plant growth conditions of a crop, and manufacturing information used for production of theproduct, and measurements of quality and quantity of desired components and undesired components in theproduct. The method includes associating the plurality of data to a record which is identified by a unique identifier. The method includes storing the record into a memory for access by one or more of a plurality of authorized users using the unique identifier. The method includes analyzing theproduct to determine the quality and quantity of desired components and undesired components in theproduct. The method includes determining concentration of cannabinoids in theproduct.

Systems and methods for integrated and comprehensive management of cannabis products

Embodiments of the invention include integrated systems and methods of evaluatingand cannabinoid products for public safety, quality control and quality assurance purposes for research and public use purposes. Embodiments of the invention facilitate suppliers and consumers of aand/or cannabinoid product to evaluate the origin, efficacy, potency, and quality of the product. Embodiments of the invention also includeprocessing center where samples of the products are analyzed for research studies to test and set parameters for third parties. Embodiments of the invention include, for example, analyzingproducts to determine quality and quantity of desired components and undesired components, determining concentrations of cannabinoids in the product, and comparing measures of components in the product against regulations. Embodiments of the invention further include, for example, an online testing facility for determine whetherproducts meet a plurality of regulations or guidelines.

Integrated systems and methods of evaluating cannabis and cannabinoid products for public safety, quality control and quality assurance purposes

The invention provides, in a general sense, a new labeling strategy employing compounds that are NSchelates conjugated to a targeting ligand, wherein the targeting ligand is a disease cell cycle targeting compound, a tumor angiogenesis targeting ligand, a tumor apoptosis targeting ligand, a disease receptor targeting ligand, amifostine, angiostatin, monoclonal antibody C225, monoclonal antibody CD31, monoclonal antibody CD40, capecitabine, a COX-2 inhibitor, deoxycytidine, fullerene, herceptin, human serum albumin, lactose, leuteinizing hormone, pyridoxal, quinazoline, thalidomide, transferrin, or trimethyl lysine. The present invention also pertains to kits employing the compounds of interest, and methods of assessing the pharmacology of an agent of interest using the present compounds.

Growing community of inventors

Houston, TX, United States of America

Jerry L Bryant, Jr